HomeAI · summaries
Storia in 5 fonti
Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Incyte to buy blood disorder drug in possibly $2B deal
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
- ·
morningstar.com
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
- ·
endpoints.news
Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
- ·
valor.globo.com
Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia
A aquisição inclui o principal projeto da Vega, o VGA039, que modula a Proteína S para melhorar a hemostasia, aumentando potencialmente a capacidade do corpo de controlar…
- ·
Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028 patent cliff.
- ·
benzinga.com
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s.